Document 0944
 DOCN  M9440944
 TI    Toxic neuropathies and myopathies.
 DT    9404
 AU    Kuncl RW; George EB; Department of Neurology, Johns Hopkins University
       School of; Medicine, Baltimore, MD 21287-7519.
 SO    Curr Opin Neurol. 1993 Oct;6(5):695-704. Unique Identifier : AIDSLINE
       MED/94122889
 AB    This review first considers toxic neuropathies of recent interest,
       including those caused by antineoplastic and antiretroviral drugs,
       agents that affect methylation reactions, vitamin and herbal
       preparations, and certain occupational exposures. The discussion points
       out the interesting phenomenon of coasting, the strategy of using
       neurotrophic factors to combat toxic neuropathies, and the inapparent
       risks in health foods. Second, it considers toxic myopathy syndromes,
       including zidovudine myopathy and its differentiation from
       HIV-associated inflammatory myopathy, cholesterol-lowering agent
       myopathies, acute myopathy with selective loss of myosin filaments due
       to neuromuscular blocking agents and corticosteroids, the eosinophilia
       myalgia syndrome, and colchicine myoneuropathy. Some of these syndromes
       illustrate important toxicologic principles about recognition of rare
       disorders, unanticipated temporal relationships with exposure, and risk
       factor assessment.
 DE    Animal  Disease Models, Animal  Human  Microscopy, Electron
       Muscles/DRUG EFFECTS/PATHOLOGY  Neuromuscular Diseases/*CHEMICALLY
       INDUCED/PATHOLOGY  Occupational Diseases/CHEMICALLY INDUCED/PATHOLOGY
       Peripheral Nerves/DRUG EFFECTS/PATHOLOGY  Polyneuritis/*CHEMICALLY
       INDUCED/PATHOLOGY  Risk Factors  Support, Non-U.S. Gov't  Support, U.S.
       Gov't, P.H.S.  JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).